ClinicalTrials.gg
Active, not recruitingNCT05776667Updated Nov 13, 2026Results posted

Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma

An interventional study of Hypofractionated Radiation Therapy in Soft Tissue Sarcoma, sponsored by Medical University of South Carolina. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment

How we know

Updated Nov 13, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 242 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
623rd of 800
15 · median 35
Started
2023
with 33 others
No phase
104 of 958
26 open now
Primary completion
2025-11
later than 37 of 240 live
Registered
833rd of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 623rd largest by enrollment of the 800 interventional ones that give a count, is one of 34 that started in 2023, is one of 104 with no phase, reaches primary completion later than 37 of the 240 other live ones, and was the 833rd registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

This study is investigating the feasibility of preoperative 5-day hypofractionated radiotherapy (HFRT) for extremity soft tissue sarcoma (STS). The primary objective is to assess the uptake of 5-day HFRT in patients with STS who are candidates for preoperative radiotherapy and limb preserving surgery. Secondary objectives include evaluation of the rates of favorable pathologic response, major wound complications, local control, acute toxicity, and 1-year late toxicity will be assessed. Exploratory objectives include evaluation of the impact of preoperative 5-day HFRT on access to care, the socio-demographic profile of the trial participants will be compared to that of extremity STS patients seen within Hollings Cancer Center (HCC) and recommended preoperative conventional fractionation radiotherapy (CFRT) in the 3 years prior to the study opening. The retention rate for radiotherapy at HCC in patients meeting trial criteria during the prior 3 years will be compared with the retention rate for radiotherapy during the study period. An exploratory analysis will measure serum SFRP2 pre- and post- radiotherapy to assess changes in response to preoperative 5-day HFRT. Changes in serum SFRP2 will be evaluated for association with a favorable pathologic response to determine the potential of serum SFRP2 as a predictive biomarker. Patient satisfaction with the decision to participate in a trial of preoperative 5-day HFRT will be assessed.

Read the detailed description

The current standard approach to the management of extremity STS is a combination of radiotherapy and limb preserving surgery. Currently guidelines recommend preoperative conventionally fractionated radiotherapy (CFRT) given at 1.8-2.0 Gy/fx, which involves 5-6 weeks of daily treatments. Preoperative hypo-fractionated radiotherapy (HFRT) is an approach that can shorten the duration of treatment. Clinical outcomes with preoperative HFRT in STS have been reported from retrospective case series, prospective institutional registries and phase I-II trials. However, preoperative HFRT has not been compared in a prospective randomized trial to CFRT and due to the rarity of extremity soft tissue sarcoma, attempts to develop such a trial would face feasibility challenges. Therefore, single arm trials of preoperative HFRT will be critical to defining the feasibility, toxicity, efficacy, and potential improvement in access to care associated with this approach.

Radiation therapy combined with wide local excision in the preoperative or postoperative setting optimizes local control for extremity STS. Preoperative radiotherapy confers a higher rate of wound complications but a lower rate of irreversible sequela such as fibrosis and lymphedema compared with postoperative radiotherapy. Resultantly, preoperative radiotherapy is the preferred approach in most cases. Preoperative radiotherapy with CFRT given at 1.8-2.0 Gy/fx, involves 5-6 weeks of daily treatments. The burden of daily travel and time away from work or care giving can be a barrier to utilization of radiotherapy. A recent analysis of the National Cancer Database demonstrated that farther distance to treatment was a negative predictor for receipt of radiotherapy in extremity STS. Sociodemographic factors such as female sex, older age (>70 years), Black race, and noncommercial insurance coverage were also negatively associated with receipt of radiotherapy. The authors summarized that radiotherapy is underutilized in the treatment of STS and that sociodemographic disparities exist in access to radiotherapy. Receipt of radiation therapy and surgery within a high volume (HV) sarcoma center has been associated with improved overall survival, while Black race and non-metropolitan residents were negative predictors for treatment within such centers. To address disparities in access to radiation therapy, the American Society for Radiation Oncology Committee on Health Equity, Diversity, and Inclusion has proposed studying novel HFRT schedules. As validation of this strategy, Kalbasi et al. increased retention of extremity STS patients within a HV sarcoma center by 3-fold with the utilization of preoperative HFRT. Further, the decreased time and travel associated with HFRT, can address an established barrier to clinical trial participation, particularly for those living remote from clinical trial sites. Clinical trial participation is particularly low in rural areas which results in these populations being underrepresented in the clinical research. A survey of South Carolina based medical researchers, identified rural residents as a group that are difficult to find and recruit to clinical trials. In a survey of urban and rural South Carolina residents, there was no difference in reported willingness to participate in clinical trials, but rural residents were more likely to perceive limited access to clinical trial sites. Investigating cancer treatment approaches that decreased the economic and logistical burdens incurred by patients, such as preoperative 5-day HFRT, may increase clinical trial participation by rural South Carolina residents and ultimately address disparities in representation of these populations in cancer research.

HFRT, using >2.2 Gy/fx, has resulted in equivalent oncologic outcomes to CFRT in other tumor sites such as breast, prostate and rectum. For STS, HFRT may confer a radiobiologic advantage in that the linear-quadratic model predicts larger doses per fraction provide better tumor control for tumors with a lower α/β ratio. For liposarcomas and rhabdomyosarcomas, their α/β ratio (\~4 Gy) is similar to breast and prostate cancer, malignancies in which HFRT has been widely adopted. While histologic variability certainly exists, most STSs have estimated α/β ratios lower than 10, suggesting increased sensitivity to larger fraction size.

Clinical outcomes with preoperative HFRT in STS have been reported from retrospective case series, prospective institutional registries and phase I-II trials. Comparing oncologic outcomes across these series is hindered by heterogeneous clinicopathological features, surgical techniques, samples sizes, and radiation fractionation schedules. However, the local control and rates of wound complications associated with HFRT and CFRT regimens appear similar as summarized Spalek and Rutkowski.

This study will utilize a 30Gy/5fx preoperative regimen as it has an estimated EQD2 of 50 Gy (based on a α/β ratio=4) and therefore would be expected to closely parallel the biologic effect of CFRT. This preoperative 5-day HFRT regimen was studied in a phase II trial at UCLA and the 2-year rates of acute wound complications were favorable compared to historical controls.

Exploratory Analysis of SFRP2 as a Predictive Biomarker:

Secreted Frizzled-Related Protein 2 (SFRP2) is a secretory protein involved in activation of the Wnt signaling pathway. Wnt signaling regulates normal embryonic development but aberrations in this pathway have been linked with tumor progression. SFRP2 is a tumor promotor that which exerts effects on endothelial cells, tumor cells and T-cells. SFRP2 has been shown to stimulate angiogenesis in endothelial cells through activation of the non-canonical Wnt/Ca2 pathway. SFRP2 mediated activation of the Wnt/Ca2 pathway results in downstream dephosphorylation of the nuclear factor of activated T-cells (NFAT). NFAT then can translocate from the cytoplasm to the nucleus where it mediates processes involving tumor cell growth, survival, invasion, and angiogenesis. Inhibition of SFRP2 has been shown to inactivate NFAT in tumor cells and imped tumor cell migration. NFAT also is involved in regulation of T-cell activity. SFRP2 has been shown to promote NFATc3, CD38 and PD-1 expression in T-cells, which are mechanisms for immunotherapeutic resistance. Monoclonal antibodies to SFPR2 in an osteosarcoma model lowered serum SFPR2 levels, lowered CD38 levels in tumor-infiltrating lymphocytes and T-cells and lowered PD-1 levels in T-cells.

SFRP2 has been identified as a tumor promotor in multiple histological subtypes of STS. In mouse angiosarcoma models, a humanized monoclonal antibody to SFRP2 has been shown to lower serum levels of the protein and inhibit tumor proliferation.

In humans with breast cancer, serum SFRP2 levels are elevated over healthy controls and correlate with increasing tumor size, presence of lymph node metastasis, increasing TMN stage and higher Ki67, a marker of proliferation.

In humans with STS, the levels of serum SFRP2 expression and the response of serum SFRP2 levels to therapeutic interventions such as radiotherapy are unknown. This study will compare serum levels of SFRP2 before and after preoperative 5-day HFRT to define levels of expression in patients with STS and assess the effect of radiotherapy on SFRP2 expression. Further, we will evaluate the association of the change in serum SFRP2 levels with extent of tumor fibrosis/hyalinization, a histologic predictor of oncologic outcome, to determine the potential of SFRP2 as a predictive biomarker for favorable pathologic response. If a preoperative predictive biomarker were established in STS, then it potentially could be utilized to intensify neoadjuvant therapies.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

Keywords

  • STS
  • HFRT
  • SFRP2
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willingness and provision of via a signed and dated copy
  2. AJCC 8th edition stage I-III confirmed STS of the extremities or trunk
  3. Male or female, aged > 18 years old
  4. Performance Status 0-3
  5. Meets screening criteria for receipt of radiotherapy
  6. Deemed eligible for wide local excision

Exclusion criteria

Exclusion Criteria:

  1. Distant disease
  2. Prior radiation therapy in the proposed treatment area
  3. Simultaneous treatment of another
  4. Planned or adjuvant chemotherapy
  5. Women who are pregnant or planning to become pregnant during study participation
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Hypofractionated Radiation Therapy

    Radiation: Hypofractionated Radiation Therapy

Interventions

  • RadiationHypofractionated Radiation Therapy

    Participants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by "standard of care" wide local excision 2-6 weeks later.

06

What researchers measure

Primary outcomes

  1. Feasibility of 5-day HFRT

    The preoperative 5-day HFRT uptake rate, defined as the proportion of eligible patients who elect to participate in the trial.

    Time frame: Up to 3 weeks

Secondary outcomes

  1. Rate of Favorable Pathologic Response

    Proportion of patients with extent of tumor fibrosis/hyalinization and infarct \> 12.5%

    Time frame: surgical resection plus 3 weeks

  2. Rate of Major Wound Complication

    Major wound complication defined according to CAN-NCIC-SR2 Multi-center trial within 6 months of surgery

    Time frame: Up to 6 months post surgery

  3. Local Control

    Local control defined as 1-year Local Recurrence Free Survival, calculated from the date of surgery to the date of 12-month follow up

    Time frame: Up to 12 months post operatively

  4. Acute Toxicity

    Acute toxicity defined by CTCAE v 5.0 assessed during radiotherapy treatment and 2 weeks following completion of radiotherapy

    Time frame: up to 2 weeks post completion of radiotherapy

  5. 1-year Late HFRT Toxicity

    1-year late toxicity defined incidence of grade \>=2 subcutaneous fibrosis, joint stiffness (RTOG/EORTC Criteria) and edema (Stern scale). Scale values are 0 - 4 with 0 is none and 4 is worst.

    Time frame: Up to 12 months post surgery

07

Results

Posted Nov 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneHypofractionated Radiation Therapy
Started15
Completed15
Not completed0

Outcome measures

PrimaryFeasibility of 5-day HFRT

The preoperative 5-day HFRT uptake rate, defined as the proportion of eligible patients who elect to participate in the trial.

Time frame:
Up to 3 weeks
Reported as:
Count of participants · Participants
Feasibility of 5-day HFRT
ParticipantsHypofractionated Radiation Therapy
Feasibility of 5-day HFRT15
SecondaryRate of Favorable Pathologic Response

Proportion of patients with extent of tumor fibrosis/hyalinization and infarct \> 12.5%

Time frame:
surgical resection plus 3 weeks
Reported as:
Count of participants · Participants
Rate of Favorable Pathologic Response
ParticipantsHypofractionated Radiation Therapy
Rate of Favorable Pathologic Response2
SecondaryRate of Major Wound Complication

Major wound complication defined according to CAN-NCIC-SR2 Multi-center trial within 6 months of surgery

Time frame:
Up to 6 months post surgery
Reported as:
Count of participants · Participants
Rate of Major Wound Complication
ParticipantsHypofractionated Radiation Therapy
Rate of Major Wound Complication5
SecondaryLocal Control

Local control defined as 1-year Local Recurrence Free Survival, calculated from the date of surgery to the date of 12-month follow up

Time frame:
Up to 12 months post operatively
Reported as:
Count of participants · Participants
Local Control
ParticipantsHypofractionated Radiation Therapy
Local Control10
SecondaryAcute Toxicity

Acute toxicity defined by CTCAE v 5.0 assessed during radiotherapy treatment and 2 weeks following completion of radiotherapy

Time frame:
up to 2 weeks post completion of radiotherapy
Reported as:
Count of participants · Participants
Acute Toxicity
ParticipantsHypofractionated Radiation Therapy
Acute toxicity during radiotherapy treatment0
Acute toxicity 2 weeks following completion of radiotherapy0
Secondary1-year Late HFRT Toxicity

1-year late toxicity defined incidence of grade \>=2 subcutaneous fibrosis, joint stiffness (RTOG/EORTC Criteria) and edema (Stern scale). Scale values are 0 - 4 with 0 is none and 4 is worst.

Time frame:
Up to 12 months post surgery
Reported as:
Count of participants · Participants
1-year Late HFRT Toxicity
ParticipantsHypofractionated Radiation Therapy
1-year late fibrosis (RTOG/EORTC)10
1-year late joint stiffness (RTOG/EORTC)6
1-year late edema (Stern scale)5

Adverse events

Collected over up to 27 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hypofractionated Radiation Therapy0/15 (0%)6/15 (40%)15/15 (100%)
Most frequent serious events
Most frequent serious events
EventHypofractionated Radiation Therapy
Wound complicationSkin and subcutaneous tissue disorders2/15
Wound infectionInfections and infestations2/15
HematomaSkin and subcutaneous tissue disorders1/15
Maggot InfestationInfections and infestations1/15
Soft tissue infectionInfections and infestations1/15
Wound dehiscenceSkin and subcutaneous tissue disorders1/15
Most frequent other events
Showing 10 of 40
Most frequent other events
EventHypofractionated Radiation Therapy
Superficial soft tissue fibrosisSkin and subcutaneous tissue disorders11/15
Dermatitis radiationSkin and subcutaneous tissue disorders10/15
Edema limbsGeneral disorders9/15
ArthralgiaMusculoskeletal and connective tissue disorders7/15
FatigueGeneral disorders7/15
Pain in extremityMusculoskeletal and connective tissue disorders5/15
DiarrheaGastrointestinal disorders4/15
ChillsGeneral disorders3/15
SeromaSkin and subcutaneous tissue disorders3/15
Wound infectionInfections and infestations3/15

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Hypofractionated Radiation Therapy
Mean61.8 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Hypofractionated Radiation Therapy
Female4
Male11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Hypofractionated Radiation Therapy
Hispanic or Latino1
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Hypofractionated Radiation Therapy
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White13
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Hypofractionated Radiation Therapy
United States15
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Nov 2025, 27 months.

Results were first posted in Nov 2026, 11 months after primary completion.

Of 145 non-industry interventional studies with no phase under Sarcoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 120. This study's 27 months is below that.

Counting every sponsor, half of 148 studies reached it within 59 months; a quarter within 34 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2023
First posted
Mar 20, 2023
StartActual
Aug 15, 2023
Primary completionActual
Nov 18, 2025
CompletionEst.
Nov 18, 2026
Results first posted
Nov 13, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 13, 2026
Enrollment
16→15
Nov 13, 2026
Eligibility
1 inclusion criterion edited, 1 added; 1 exclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedWillingness and provision of informed consent via a signed and dated copy
  • EditedAJCC 8th edition stage I-III histologically confirmed STS of the extremityextremities or trunk
Exclusion criteria
  • AddedWomen who are pregnant or planning to become pregnant during study participation
Nov 13, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameFeasibility of 5-day HFRTUp to 3 years → Up to 3 weeks
Nov 13, 2026
Documents
Secondary outcomes
4 edited, 1 time frame changed, 5 removed
What changed in the outcomes
  • EditedRate of favorable pathologic responseFavorable Pathologic ResponseTime frame: Up to 3 years → surgical resection plus 3 weeks
  • EditedRate of major wound complicationMajor Wound ComplicationTime frame: Up to 3 years → Up to 6 months post surgery
  • EditedAcute toxicityToxicityTime frame: Up to 3 years → up to 2 weeks post completion of radiotherapy
  • Edited1-year lateLate HFRT toxicityToxicityTime frame: Up to 3 years → Up to 12 months post surgery
  • Time frameLocal ControlUp to 3 years → Up to 12 months post operatively
  • Removedother outcomeComparison of socio-demographic profilesTime frame: Up to 3 years
  • Removedother outcomeComparison of retention rate for radiotherapy at the clinical siteTime frame: Up to 3 years
  • Removedother outcomeComparison of serum SFRP2 levels before and after preoperative 5-Day HFRTTime frame: Up to 3 years
  • Removedother outcomeEvaluating patient satisfaction with trial participationTime frame: Up to 3 years
  • Removedother outcomeAssessing patient rated importance of short course of radiotherapy in decision to participate in studyTime frame: Up to 3 years
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Results posted
    Enrollment 16→15
    Eligibility 1 inclusion criterion edited, 1 added; 1 exclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedWillingness and provision of informed consent via a signed and dated copy
    • EditedAJCC 8th edition stage I-III histologically confirmed STS of the extremityextremities or trunk
    Exclusion criteria
    • AddedWomen who are pregnant or planning to become pregnant during study participation
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameFeasibility of 5-day HFRTUp to 3 years → Up to 3 weeks
    Secondary outcomes 4 edited, 1 time frame changed, 5 removed
    What changed in the outcomes
    • EditedRate of favorable pathologic responseFavorable Pathologic ResponseTime frame: Up to 3 years → surgical resection plus 3 weeks
    • EditedRate of major wound complicationMajor Wound ComplicationTime frame: Up to 3 years → Up to 6 months post surgery
    • EditedAcute toxicityToxicityTime frame: Up to 3 years → up to 2 weeks post completion of radiotherapy
    • Edited1-year lateLate HFRT toxicityToxicityTime frame: Up to 3 years → Up to 12 months post surgery
    • Time frameLocal ControlUp to 3 years → Up to 12 months post operatively
    • Removedother outcomeComparison of socio-demographic profilesTime frame: Up to 3 years
    • Removedother outcomeComparison of retention rate for radiotherapy at the clinical siteTime frame: Up to 3 years
    • Removedother outcomeComparison of serum SFRP2 levels before and after preoperative 5-Day HFRTTime frame: Up to 3 years
    • Removedother outcomeEvaluating patient satisfaction with trial participationTime frame: Up to 3 years
    • Removedother outcomeAssessing patient rated importance of short course of radiotherapy in decision to participate in studyTime frame: Up to 3 years
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05776667
Responsible party
Jennifer Lynn Harper (Professor of Radiation Oncology, Medical University of South Carolina) — Principal investigator
First posted
Mar 20, 2023
Start date
Aug 15, 2023
Primary completion
Nov 18, 2025
Completion
Nov 18, 2026 (estimated)
Results posted
Nov 13, 2026
Last update
Nov 13, 2026

Study contacts

Jennifer Harper, MD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion